ASX - Delayed Quote AUD

Aroa Biosurgery Limited (ARX.AX)

Compare
0.5700 0.0000 (0.00%)
As of 2:57 PM GMT+11. Market Open.
Loading Chart for ARX.AX
DELL
  • Previous Close 0.5700
  • Open 0.5750
  • Bid 0.5650 x --
  • Ask 0.5850 x --
  • Day's Range 0.5600 - 0.5750
  • 52 Week Range 0.4400 - 0.8700
  • Volume 46,754
  • Avg. Volume 684,767
  • Market Cap (intraday) 196.593M
  • Beta (5Y Monthly) 0.69
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date Nov 26, 2024 - Dec 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.00

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

aroa.com

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: ARX.AX

View More

Performance Overview: ARX.AX

Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ARX.AX
31.33%
S&P/ASX 200 [XJO]
8.04%

1-Year Return

ARX.AX
30.06%
S&P/ASX 200 [XJO]
17.55%

3-Year Return

ARX.AX
47.71%
S&P/ASX 200 [XJO]
9.98%

5-Year Return

ARX.AX
59.29%
S&P/ASX 200 [XJO]
36.15%

Compare To: ARX.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ARX.AX

View More

Valuation Measures

Annual
As of 11/6/2024
  • Market Cap

    196.59M

  • Enterprise Value

    175.69M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.09

  • Price/Book (mrq)

    2.26

  • Enterprise Value/Revenue

    2.77

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -15.39%

  • Return on Assets (ttm)

    -5.86%

  • Return on Equity (ttm)

    -10.80%

  • Revenue (ttm)

    69.07M

  • Net Income Avi to Common (ttm)

    -10.63M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    30.23M

  • Total Debt/Equity (mrq)

    7.83%

  • Levered Free Cash Flow (ttm)

    -11.84M

Research Analysis: ARX.AX

View More

Company Insights: ARX.AX

Research Reports: ARX.AX

View More

People Also Watch